Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of ...

Spanish biopharmaceutical company Biofabri and nonprofit scientific research organization IAVI announced today that the first ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of ...

Innovative research at Weill Cornell Medicine introduces engineered mycobacteria strains with 'kill switches' for safer TB ...

Researchers have engineered two mycobacterial strains with built-in kill switches that trigger self-destruction after immune ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...

A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

A new study found that some medications could have the unintended benefit of reducing dementia risk, while others could ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...